Abstract
Adenoviruses (Ads) are robust vectors for therapeutic applications and vaccines, but their use can be limited by differences in their in vitro and in vivo pharmacologies. This review emphasizes that there is not just one Ad, but a whole virome of diverse viruses that can be used as therapeutics. It discusses that true vector targeting involves not only retargeting viruses, but importantly also detargeting the viruses from off-target cells.
Keywords:
Ad serotypes; detargeting; gain of function; liver; retargeting; sequestration; serotypes.
© 2020 Federation of European Biochemical Societies.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Review
MeSH terms
-
Adenoviridae / classification
-
Adenoviridae / genetics*
-
Animals
-
Biotinylation
-
Capsid Proteins / genetics
-
Genetic Vectors / administration & dosage
-
Genetic Vectors / genetics*
-
Genetic Vectors / pharmacokinetics*
-
Humans
-
Injections, Intravenous
-
Ligands
-
Liver / drug effects
-
Microorganisms, Genetically-Modified
-
Oncolytic Viruses / genetics
-
Peptide Library
-
Tissue Distribution
-
Vaccines / administration & dosage
-
Vaccines / genetics
Substances
-
Capsid Proteins
-
Ligands
-
Peptide Library
-
Vaccines